Case Report: Simultaneously Induced Neutropenia and Hemolysis After a Single Metamizole Dose.

IF 2.2 4区医学 Q3 PHARMACOLOGY & PHARMACY

Drugs in Research & Development Pub Date : 2023-06-01 DOI:10.1007/s40268-023-00415-9

Raphael Allgaier, Arne Kandulski, Karsten Gülow, Lars Maier, Martina Müller, Hauke Christian Tews

引用次数: 1

Abstract

Background and objective: Metamizole is a non-opioid ampyrone sulfonate compound with potent analgesic, antipyretic, and spasmolytic effects. Agranulocytosis is a rare life-threatening complication of metamizole.

Case: Here, we present the case of a 62-year-old patient who developed agranulocytosis as well as hemolysis after a single administration of metamizole.

Conclusion: This case illustrates the inherent allergic potential of metamizole and its effects on different hematopoietic cell types.

Abstract Image

查看原文本刊更多论文

病例报告:单次给药后同时诱导中性粒细胞减少和溶血。

背景和目的:Metamizole是一种非阿片类氨吡酮磺酸化合物，具有有效的镇痛、解热和解痉作用。粒细胞缺乏症是一种罕见的危及生命的并发症。病例:在这里，我们提出的情况下，62岁的病人谁发展为粒细胞缺乏症，以及溶血后，单次给予安咪唑。结论:本病例说明了metamizole固有的过敏潜力及其对不同造血细胞类型的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drugs in Research & Development Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

5.10

自引率

0.00%

发文量

审稿时长

8 weeks

期刊介绍： Drugs in R&D is an international, peer reviewed, open access, online only journal, and provides timely information from all phases of drug research and development that will inform clinical practice. Healthcare decision makers are thus provided with knowledge about the developing place of a drug in therapy. The Journal includes: Clinical research on new and established drugs; Preclinical research of direct relevance to clinical drug development; Short communications and case study reports that meet the above criteria will also be considered; Reviews may also be considered.